Efficacy and safety of ruxolitinib for graft-versus-host disease prophylaxis in patients with aplastic anemia undergoing PBSC-only allogeneic stem cell transplantation: a prospective phase II study
The peri-transplantation addition of ruxolitinib to the standard GVHD prophylaxis regimen in PB-HSCT for AA patients has shown to be a safe and effective approach to reducing both the incidence of aGVHD, while improving patient outcomes. Our study suggests that ruxolitinib may offer a promising strategy for improving survival and immune recovery. Trial registration clinicaltrials.gov identifier: NCT05914714.
Authors
- S. feng
- Runzhi Ma (ORCID: https://orcid.org/0000-0003-0586-4222)
- Erlie Jiang (ORCID: https://orcid.org/0000-0003-0237-6063)
- Weihua Zhai
- Mingzhe Han
- Qiaoling Ma
- Guoyou Qin
- Yanhong Zhao
- Lining Zhang
- Xiaoyu Zhang
- Aiming Pang
- Lulu Pan
- Donglin Yang
- Ping Zhang
- Gang Li
- YING ZHANG
- Yi He
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- QIMR Berghofer Medical Research Institute (AU)
- Fudan University (CN)
- Fred Hutch Cancer Center (US)
- Tianjin Anding Hospital (CN)
- Ministry of Education (KR)
- Institute of Hematology & Blood Diseases Hospital (CN)
Publication Details
- Journal
- Experimental Hematology and Oncology
- Published
- 2026-03-08
- DOI
- https://doi.org/10.1186/s40164-026-00753-9
- Primary Topic
- Hematopoietic Stem Cell Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Tianjin City
- National Science and Technology Major Project
- Fundamental Research Funds for the Central Universities